CCRM and panCELLa partner on new master cell banks

Collaborators aim to accelerate development of novel cell therapies and aid both academia and industry
| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
TORONTO—Recently, panCELLa and CCRM executed a collaboration agreement around the use of novel technology to generate commercial-use and clinical-grade induced pluripotent stem cell (iPSC) lines that will be made available to academia and industry to enable the development of new therapies.
 
“panCELLa is an innovative company and a key partner in our local ecosystem. We’re pleased to support their efforts to develop novel engineered cell lines that will enable multiple indications representing significant unmet needs,” says Michael May, president and CEO of CCRM. “This collaboration will also support other companies in our network, as CCRM and panCELLa will work together to make these high-quality cGMP lines available to the global biotechnology community.”
 
An early-stage biotechnology company, panCELLa spun out of research conducted at the Sinai Health System in Toronto. It will produce novel versions of the lines that are engineered for safety and the ability to evade the immune system. CCRM, a leader in developing and commercializing regenerative medicine-based technologies and cell and gene therapies, will develop master cell banks in the Centre for Cell and Vector Production (CCVP), a cGMP facility that CCRM operates with the University Health Network. The partners will both have the option to license these lines out to academic and industry partners interested in working with clinical-grade iPSCs.
 
“The long-standing support and commitment of CCRM to our technology was a critical component to our success in raising funds,” noted Dr. Andras Nagy, a co-founder of panCELLa. “This has enabled panCELLa to advance its platforms, making them more widely available to the regenerative medicine market. We look forward to continuing this fruitful relationship.”
 
CCVP is the largest cGMP facility in Toronto focused exclusively on manufacturing cells and viral vectors for Phase 1/2 clinical trials. With 10 class B clean rooms, it is designed to be Health Canada-, FDA- and EMA-compliant.

Related Topics

Published In

Volume 16 - Issue 5 | May 2020

May 2020

May 2020 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Close-up illustration of clustered, irregularly shaped 3D cell structures resembling organoids, displayed in a blue-toned background.
Machine learning-powered image analysis makes it possible to automatically and reliably quantify complex 3D cell structures.
Illustration of a glowing human brain with interconnected neural networks and bright data points, set against a dark, digital background.
Take a closer look at modern techniques that reveal when, where, and how neurons communicate in real time.
Gloved hand holding a petri dish containing red liquid culture medium against a light blue background.
As global regulations shift toward animal-free testing, how can researchers develop more biologically relevant in vitro models to advance drug discovery?
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue